This story has been updated to clarify the current state of the Tissue of Origin test formerly of Pathwork Diagnostics, now owned and marketed by Response Genetics.

NEW YORK (GenomeWeb) — Modeling conducted by the Partnership for Health Analytic Research and funded by BioTheranostics has found that the company's CancerType ID test, a 92-gene assay to determine the origin of cancers of unknown primary site, is cost-effective and improves patient care.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

At her blog, Sally Rockey dives into National Institutes of Health funding data.

In PNAS this week: ancestry and admixture in Brazilians, characterization of novel double-stranded RNA mycovirus, and more.

Researchers report that what scents someone picks up can reflect their complement of immune genes.

The New York Times examines ethics and China's push to lead biomedical research.